- Home
- SDA vs APLT Comparison
SDA vs APLT Comparison
Compare SDA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDA
- APLT
- Stock Information
- Founded
- SDA 2007
- APLT 2016
- Country
- SDA China
- APLT United States
- Employees
- SDA N/A
- APLT N/A
- Industry
- SDA Blank Checks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- SDA Finance
- APLT Health Care
- Exchange
- SDA Nasdaq
- APLT Nasdaq
- Market Cap
- SDA 263.8M
- APLT 44.0M
- IPO Year
- SDA N/A
- APLT 2019
- Fundamental
- Price
- SDA $2.43
- APLT $0.42
- Analyst Decision
- SDA Buy
- APLT Buy
- Analyst Count
- SDA 1
- APLT 7
- Target Price
- SDA $3.50
- APLT $6.10
- AVG Volume (30 Days)
- SDA 100.6K
- APLT 2.7M
- Earning Date
- SDA 09-15-2025
- APLT 08-06-2025
- Dividend Yield
- SDA N/A
- APLT N/A
- EPS Growth
- SDA N/A
- APLT N/A
- EPS
- SDA N/A
- APLT N/A
- Revenue
- SDA $458,905,000.00
- APLT $265,000.00
- Revenue This Year
- SDA $20.77
- APLT $1,768.13
- Revenue Next Year
- SDA $19.32
- APLT $292.85
- P/E Ratio
- SDA N/A
- APLT N/A
- Revenue Growth
- SDA 24.15
- APLT N/A
- 52 Week Low
- SDA $2.30
- APLT $0.30
- 52 Week High
- SDA $11.74
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- SDA 39.27
- APLT 60.22
- Support Level
- SDA $2.30
- APLT $0.32
- Resistance Level
- SDA $2.58
- APLT $0.36
- Average True Range (ATR)
- SDA 0.16
- APLT 0.04
- MACD
- SDA -0.00
- APLT 0.01
- Stochastic Oscillator
- SDA 32.50
- APLT 88.67
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.